Last Published:  07/31/19 10:05:33 AM (Central)
Short Title: CBS Data Mining CMs: Fam Hist/Prev Med/Individual Sensitivities/Exposures/Monitoring Exposures
Responsible HRP Element: Human Factors and Behavioral Performance
Collaborating Org(s):
Human Health Countermeasures (HHC) Element
Other:
Space Radiation (SR) Element
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Directed
Aims:

Robust identification of current research that identifies both pre-mission risks and vulnerabilities for individuals due to family history, previous exposures, preventive medicine, sensitivites, genotype and phenotype within the context of integrated risk and risks posed to crew health and safety and the countermeaaures needed should medical conditions arise.  For example, in major depressive disorder, high levels of histone deacetylase 5 prior to treatment initiation appear to be a robust marker for treatment response (Iga et al., 2007; Hobara et al., 2010; Belzeaux et al., 2010). Levels of cyclic-adenosine monophosphate (cAMP) response element binding protein 1 (Iga et al., 2007), histone deacetylase 2 (Hobara et al., 2010), serotonergic markers (Belzeaux et al., 2010), a panel of four gene expression pro les (Belzeaux et al., 2012), and interferon regulatory factor 7 (Mamdani et al., 2011) have variously been reported to change following treatment with antidepressants.

-Belzeaux R, Formisano-Tre´ziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Fe´ron F, Naudin J, Ibrahim EC (2010) Clinical variations modulate patterns of gene expression and de ne blood biomarkers in major depression. J Psychiatr Res 44:1205–1213.
-Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC (2012) Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185.
-Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suetsugi M, Watanabe Y (2010) Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 44:263–270.
-Iga Ji, Ueno Si, Yamauchi K, Numata S, Kinouchi S, Tayoshi- Shibuya S, Song H, Ohmori T (2007) Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 31:628–632.
-Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C, Turecki G (2011) Gene expression biomarkers of response to citalo- pram treatment in major depressive disorder. Transl Psychiatry 1:e13.

Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
GapCBS-CNS - 1: Are there significant adverse changes in CNS performance in the context and time scale of spaceflight operations? If so, how is significance defined, and which neuropsychological domains are affected? Is there a significant probability that space radiation exposure would result in adverse changes? What are the pathways and mechanisms of change?
GapCBS-CNS - 2: Does space radiation exposure elicit key events in adverse outcome pathways associated with neurological diseases? What are the key events or hallmarks, their time sequence and their associated biomarkers (in-flight or post-flight)?
GapCBS-CNS - 4: What are the most effective medical or dietary countermeasures to mitigate CNS risks? By what mechanisms are the countermeasures likely to work?
GapCBS-CNS - 5: How can new knowledge and data from molecular, cellular, tissue and animal models of acute CNS adverse changes or clinical human data, including altered motor and cognitive function and behavioral changes be used to estimate acute CNS risks to astronauts from GCR and SPE?
GapCBS-CNS - 8: Are there significant CNS risks from combined space radiation and other physiological or space flight factors, e.g., psychological (isolation and confinement), altered gravity (micro-gravity), stress, sleep deficiency, altered circadian rhythms, hypercapnea, altered immune, endocrine and metabolic function, or other?
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures

RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
GapCBS-BMed1: We need to identify and validate countermeasures that promote individual behavioral health and performance during exploration class missions.
GapCBS-BMed2: We need to identify and validate measures to monitor behavioral health and performance during exploration class missions to determine acceptable thresholds for these measures.
GapCBS-BMed3: We need to identify and quantify the key threats to and promoters of mission relevant behavioral health and performance during autonomous, long duration and/or long distance exploration missions.
GapCBS-CNS - 1: Are there significant adverse changes in CNS performance in the context and time scale of spaceflight operations? If so, how is significance defined, and which neuropsychological domains are affected? Is there a significant probability that space radiation exposure would result in adverse changes? What are the pathways and mechanisms of change?
GapCBS-CNS - 2: Does space radiation exposure elicit key events in adverse outcome pathways associated with neurological diseases? What are the key events or hallmarks, their time sequence and their associated biomarkers (in-flight or post-flight)?
GapCBS-CNS - 4: What are the most effective medical or dietary countermeasures to mitigate CNS risks? By what mechanisms are the countermeasures likely to work?
GapCBS-CNS - 5: How can new knowledge and data from molecular, cellular, tissue and animal models of acute CNS adverse changes or clinical human data, including altered motor and cognitive function and behavioral changes be used to estimate acute CNS risks to astronauts from GCR and SPE?
GapCBS-CNS - 8: Are there significant CNS risks from combined space radiation and other physiological or space flight factors, e.g., psychological (isolation and confinement), altered gravity (micro-gravity), stress, sleep deficiency, altered circadian rhythms, hypercapnea, altered immune, endocrine and metabolic function, or other?
GapCBS-SM2.1: Determine the changes in sensorimotor function over the course of a mission and during recovery after landing.
GapCBS-SM7.1: Determine if there are decrements in performance on functional tasks after long-duration spaceflight. Determine how changes in physiological function, exercise activity, and/or clinical data account for these decrements.
GapCBS-SM24: Determine if the individual capacity to produce adaptive change (rate and extent) in sensorimotor function to transitions in gravitational environments can be predicted with preflight tests of sensorimotor adaptability.
GapCBS-SM28: Develop a sensorimotor countermeasure system integrated with current exercise modalities to mitigate performance decrements during and after spaceflight.
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures

RiskRisk of Impaired Control of Spacecraft/Associated Systems and Decreased Mobility Due to Vestibular/Sensorimotor Alterations Associated with Spaceflight
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures

RiskRisk of Impaired Performance Due to Reduced Muscle Mass, Strength & Endurance
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures